Pharma Pioneer

Walden Biosciences Reveals Favorable Preliminary Results from Phase 1+ Trial of WAL0921 for Kidney Disease Therapy

16 May 2024
2 min read

April 15, 2024 —Walden Biosciences, a private clinical development company, has reported positive results from its Phase 1+ study of WAL0921, a humanized monoclonal antibody designed to bind and inhibit the pathological activity of soluble urokinase plasminogen activator receptor (suPAR), which is linked to kidney diseases. The study, which involved 40 healthy subjects, showed that WAL0921 was safe and effective in rapidly reducing circulating free suPAR levels in a dose-dependent manner. This finding suggests that WAL0921 could offer a new therapeutic approach for various kidney conditions. 

The Phase 1+ clinical trial was a single-center, placebo-controlled study that assessed the safety, pharmacokinetics, and pharmacodynamics of WAL0921. Andrew Blair, M.D., Walden's Chief Medical Officer, highlighted the significance of the study's findings, stating that WAL0921's ability to target suPAR directly could represent a novel treatment strategy for kidney diseases. 

Walden Biosciences plans to move forward with a Phase 2 Basket study for glomerular kidney diseases in the second quarter of 2024, based on the promising results. The company specializes in developing transformative therapies for kidney diseases, focusing on treatments that prevent damage, slow disease progression, and restore kidney function. Walden's pipeline includes a monoclonal antibody that targets suPAR, a small molecule aimed at restoring dynamin function, and a novel anti-fibrotic biologic in preclinical research. These programs aim to provide breakthrough, disease-modifying therapies that can be combined with standard care to improve kidney disease treatment outcomes. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Preliminary Findings from Phase 1/2 Trial of Gritstone's Universal Neoantigen Vaccine Approach (SLATE) Featured in Nature Medicine
Pharma Pioneer
3 min read
Preliminary Findings from Phase 1/2 Trial of Gritstone's Universal Neoantigen Vaccine Approach (SLATE) Featured in Nature Medicine
16 May 2024
April 15, 2024 —A recent publication in Nature Medicine has highlighted the advancements in vaccine design, specifically focusing on Gritstone bio's neoantigen platform, SLATE.
Read →
Encouraging GTX-102 Trial Results in Angelman Syndrome Patients from Phase 1/2 Study by Ultragenyx
Pharma Pioneer
2 min read
Encouraging GTX-102 Trial Results in Angelman Syndrome Patients from Phase 1/2 Study by Ultragenyx
16 May 2024
April 15, 2024 —In a recent study, patients with Angelman syndrome demonstrated significant improvements in various areas after treatment with GTX-102.
Read →
TransCode Receives FDA Approval to Launch Phase 1/2 Study of TTX-MC138 for Advanced Solid Tumor Patients
Pharma Pioneer
2 min read
TransCode Receives FDA Approval to Launch Phase 1/2 Study of TTX-MC138 for Advanced Solid Tumor Patients
16 May 2024
TransCode Therapeutics, an RNA oncology company, has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase 1/2 clinical trial for its lead therapeutic candidate, TTX-MC138.
Read →
ORIC Initiates Dosing in Phase 1b Expansion for ORIC-114 in NSCLC Patients with Specific Mutations
Pharma Pioneer
2 min read
ORIC Initiates Dosing in Phase 1b Expansion for ORIC-114 in NSCLC Patients with Specific Mutations
16 May 2024
April 15, 2024 — ORIC Pharmaceuticals, a clinical-stage oncology company, has completed the dose escalation phase of its Phase 1b trial for ORIC-114.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.